The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare Cancers.

Abstract

Rare cancers account for 27% of neoplasms diagnosed each year, and 25% of cancer-related deaths in the United States. However, rare cancers show some of the highest response rates to targeted therapies, probably due to identification of oncogenic drivers with little interpatient variability. Although the low incidence of rare cancers makes large-scale… (More)
DOI: 10.1053/j.seminoncol.2015.07.010

Topics

Cite this paper

@article{Schott2015TheNC, title={The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare Cancers.}, author={Anne F. Schott and John J. Welch and Claire F. Verschraegen and Razelle Kurzrock}, journal={Seminars in oncology}, year={2015}, volume={42 5}, pages={731-9} }